Roche Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas Schinecker
- Full Time Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Grenzacherstrasse 124 Basel BS Switzerland 4070
- IPO Date
- Aug 3, 2012
- Website
- roche.com
- Similar Companies
- Business
- Roche Holding AG is a Swiss multinational healthcare company that discovers, develops, and markets innovative medicines and diagnostic tests. The company operates through two primary segments: Pharmaceuticals, which focuses on oncology, immunology, infectious diseases, ophthalmology, and neurology; and Diagnostics, which provides clinical chemistry, coagulation, and molecular diagnostics solutions. Its core products and services include pharmaceutical brands such as Tecentriq (atezolizumab) for cancer immunotherapy, Hemlibra (emicizumab) for hemophilia A, Ocrevus (ocrelizumab) for multiple sclerosis, Evrysdi (risdiplam) for spinal muscular atrophy, and Actemra/RoActemra (tocilizumab) for rheumatoid arthritis and cytokine release syndrome; diagnostic offerings encompass the cobas platform for in vitro diagnostics, including cobas pro integrated solutions, Accu-Chek for diabetes management, and Ventana for pathology testing. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland, with global operations spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East, serving healthcare professionals, patients, and research institutions. In recent developments, the company expanded its diagnostics portfolio through the 2024 launch of the cobas 5800 analyser system for high-volume clinical chemistry testing and strengthened its oncology pipeline via a strategic collaboration with Regeneron Pharmaceuticals announced in late 2024 to co-develop faricimab for additional indications; additionally, Roche completed the acquisition of Poseida Therapeutics in mid-2025 for $1.5 billion to bolster its cell therapy capabilities in hematology and solid tumors.
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
U.S.-Iran deal will stick despite being a ‘bad, bad deal', says David Roche
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
FDA approves first generic version of Roche's flu drug
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
Nurix Therapeutics Deal With Roche Is Worth Betting On
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know
Roche sticks to German investment after Eli Lilly cuts
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do